14 results for "History"

Preterm Labor and the effect of the Cervilenze Device

Currently, it is difficult to predict which pregnant women with symptoms of preterm (early) labor will actually experience preterm delivery of the baby. Length of the cervix (the opening to the uterus or womb) in pregnant women has been shown to be one of the risk factors associated with delivering a baby preterm. CerviLenz is a simple, single use device approved by the FDA to measure cervical length. The purpose of the study is to see how well the Cervilenz measurement of cervical length correlates with preterm delivery.

FMD Registry

Data registry to determine the natural course of fibromuscular dysplasia and to determine which procedures are more effective to relieve symptoms and reduce adverse outcomes.

invested

INVESTED will test the hypothesis that high dose trivalent influenza vaccine will reduce cardiopulmonary events to a greater extent than standard dose quadrivalent influenza vaccine in high-risk cardiovascular patients with a recent history of myocardial infarction or heart failure. The trial will enroll 9300 participants over one Vanguard (pilot) season and three additional influenza seasons.

Please note: we only enroll/recruit patients between the months of August & December.

PARADISE-MI (Prospective ARNI vs ACE Inhibitor Trial to Determine Superiority in Reducing Heart Fail

The purpose of this study is to evaluate the efficacy and safety of LCZ696 titrated to a target dose of 200 mg twice daily, compared to ramipril titrated to a target dose of 5 mg twice daily, in addition to conventional post-AMI treatment, in reducing the occurrence of composite endpoint of CV death, HF hospitalization and outpatient HF (time-to-first event analysis) in post-AMI patients with evidence of LV systolic dysfunction and/or pulmonary congestion, with no known prior history of chronic HF.

Preterm Preeclampsia and the effects of Recombinant Human Antithrombin (Atryn)

The purpose of this study is to evaluate the safety and effectiveness of ATryn in subjects with preterm preeclampsia. This study involves research to assess if ATryn can:

  • increase the time the baby stays in the womb
  • decrease problems the mother may experience
  • improve the health and well-being of the baby

CREST-2

This trial is testing that intensive medical management differs from the combination of CEA and intensive medical management in preventing the primary endpoint in patients with high-grade asymptomatic carotid stenosis and to test that intensive medical management differs from the combination of CAS and intensive medical management in preventing the primary endpoint in patients with high-grade asymptomatic carotid stenosis.

USA-MCI GON-1.01: Ovarian Cancer and the Effects of Screening Using Gynecologic Fluids and Mucus

In this Phase II biomarker validation study we will further refine and validate these biomarkers using a new collection of samples from at least 200 ovarian cancer cases with epithelial ovarian cancer (endometroid and papillary serous histology, most common) and comparing these against 600 patients with a diagnosis of a benign adnexal mass that enter the clinics during the same time period. Patient samples will be collected on their first visit to the gynecologic oncologist at a number of collaborating clinics. Final processing of all of the samples will be performed within the proteomics research facilities of the Mitchell Cancer Institute using Selected Reaction Monitoring (SRM, with mass spectrometry) based on the refined set of makers statistically selected within the first aim. Biomarkers validated within this study will be compared with the well accepted CA-125 data for the patients. The research involves a three year validation and may allow detection of this cancer at a very early stage when the survival is as high as 90%. One aim examines a self-taken test that could allow its use in medically underrepresented and rural areas.

Click here to download the Fast Facts

S1400: A Biomarker-Driven Master Protocol for Squamous Cell Lung Cancer

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid "Master Protocol" (S1400). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes a "non-match" sub-study which will include all screened patients not eligible for any of the biomarker-driven sub-studies. This sub-study will compare a non-match therapy to standard of care also with the goal of approval.

Click here to download the Fast Facts

NSABP B-55: Breast Cancer, BRCA1/2 Mutation and the Effects of Olaparib

Olaparib treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy

Click here to download the Fast Facts

RTOG-0924: Prostate Cancer and the Effects of Androgen-Deprivation Therapy and Radiation Therapy

Androgens can cause the growth of prostate cancer cells. Androgen deprivation therapy may stop the adrenal glands from making androgens. Radiation therapy uses high-energy X-Rays to kill tumor cells. This randomized phase III trial studies androgen-deprivation therapy and radiation therapy in treating patients with prostate cancer.

Click here to download the Fast Facts

A011202: Node Positive Breast Cancer and the effects of Axillary Lymph Node Dissection Vs. Axillary Radiation

This randomized phase III trial studies axillary lymph node dissection to see how well it works compared to axillary radiation therapy in treating patients with node-positive breast cancer treated with neoadjuvant chemotherapy followed by surgery. Lymph node dissection may remove cancer cells that have spread to nearby lymph nodes in patients with breast cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. This study will evaluate whether radiation therapy is as effective as lymph node dissection.

Click here to download the Fast Facts

NSABP B-51: Early Stage Breast Cancer and the Effects of Standard vs. Comprehensive Radiation

This randomized phase III trial studies standard or comprehensive radiation therapy in treating patients with early-stage breast cancer who have undergone surgery. Radiation therapy uses high-energy x rays to kill tumor cells. It is not yet known whether comprehensive radiation therapy is more effective than standard radiation therapy in treating patients with breast cancer.

Click here to download the Fast Facts

E1910: BCR-ABL Negative B Lineage ALL and the Effects of Blinatumomab

This randomized phase III trial studies combination chemotherapy with blinatumomab to see how well it works compared to induction chemotherapy alone in treating patients with newly diagnosed breakpoint cluster region (BCR)-c-abl oncogene 1, non-receptor tyrosine kinase (ABL)-negative B lineage acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as blinatumomab, may block cancer growth in different ways by targeting certain cells. It is not yet known whether combination chemotherapy is more effective with or without blinatumomab in treating newly diagnosed acute lymphoblastic leukemia.

Click here to download the Fast Facts

S1207: Hormone-Positive Breast Cancer and the Effects of Everolimus with Endocrine Therapy

Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen citrate, goserelin acetate, leuprolide acetate, anastrozole, letrozole, or exemestane, may fight breast cancer by lowering the amount of estrogen the body makes. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet know whether hormone therapy is more effective when given with or without everolimus in treating breast cancer.

This randomized phase III trial studies how well giving hormone therapy together with or without everolimus work in treating patients with breast cancer.

Click here to download the Fast Facts